Faron Pharmaceuticals goes back to shareholders – with weeks of cash left and potentially historic blood cancer data

An 80 million share rights offering authorized in Turku signals a company racing against its own runway

On March 2, shareholders of Faron Pharmaceuticals (AIM: FARN, First North: FARON) voted to authorize the Board to issue up to 80 million new shares in a rights offering, valid until June 30, 2026. The announcement, filed on Investegate, read like routine corporate governance. It is anything but.

Working with a deadline in mind

According to the company’s own 2025 financial statements release, published this week, the Directors estimate that cash held by the group will be sufficient to support current activities only until Q2 2026. That’s doesn’t seem like a comfortable deadline.

The situation has been deteriorating for months. As recently as November 2025, before drawing on a second convertible bond tranche, Faron’s cash position stood in a position that need the subsequent bond tranche, which provided €9.25 million in breathing room, extending the runway — but only to around May 2026, according to analysis by Rose Garden Capital.

The other side of pharma financing

As we reported yesterday, UroGen Pharma secured a $250 million senior secured loan from specialist lender BioPharma Credit and Pharmakon Advisors — non-dilutive debt financing backed by a marketed product generating nearly $100 million in annual revenue. That’s the luxury end of pharma capital markets: a company with cash flows, borrowing against them at 8.25% fixed, shareholders untouched.

Faron is the other end of that spectrum. A clinical-stage biotech with no marketed product, no revenue, and a drug that hasn’t yet crossed the Phase III finish line. When you’re in that position, you can’t call Pharmakon. You go back to your own shareholders, hat in hand, and ask them to believe in the science for another year.

That’s what this rights offering is. And the question for investors is whether the science is worth believing in.

The case that it is

Bexmarilimab — Faron’s lead asset, a novel immunotherapy targeting Clever-1 receptors on immunosuppressive macrophages — has produced clinical data that is hard to dismiss. In 2025, efficacy results from the BEXMAB Phase I/II trial were presented as oral presentations at ASCO, EHA, ESMO, and ASH — four of the world’s most prestigious oncology congresses — with results described as among the highest ever reported in HR-MDS prospective trials.

Both the EMA and FDA have granted bexmarilimab orphan drug designation for high-risk MDS, as noted in the Faron financial statements release. The company also held an End of Phase 2 meeting with the FDA in late 2025 and received positive and valuable feedback on its clinical development path. That’s a direct regulatory green light toward a pivotal Phase III trial.

Analyst Patrick Trucchio at H.C. Wainwright has reiterated a Buy rating on Faron with a £10 price target, citing a de-risked development path and strong BEXMAB efficacy. Against a current share price of around £2, that’s a five-fold upside call — if the Phase III delivers.

The risk investors must price

The rights offering itself is dilutive by definition — 80 million new shares against a current float of approximately 116 million represents potential dilution of nearly 70%. Existing shareholders who don’t participate will see their stake significantly reduced. Those who do participate are essentially making a Phase III bet on a drug with outstanding early data but no guarantee of registrational success.

The company’s CEO has framed 2026 around two themes: advancing bexmarilimab in HR-MDS toward Phase III, and demonstrating its potential in solid tumours. Both ambitions require capital that the company does not currently have.

Bottom line for investors

Faron is a high-risk, high-conviction play. The data is real, the regulatory path is clearer than it has ever been, and the unmet need in HR-MDS is severe — current standard of care delivers a median overall survival of just 5-6 months in relapsed patients. If bexmarilimab can consistently replicate its Phase I/II results in a registrational trial, it’s a genuinely important drug.